The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia
Abstract
Chronic myeloid leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22 called the Philadelphia (Ph) chromosome. In 2–10% of the cases, this chimeric gene is generated by variant rearrangements, involving 9q34, 22q11, and one or several other genomic regions. All chromosomes have been described as participating in these variants, but there is a marked breakpoint clustering to chromosome bands 1p36, 3p21, 5q13, 6p21, 9q22, 11q13, 12p13, 17p13, 17q21, 17q25, 19q13, 21q22, 22q12, and 22q13. Despite their genetically complex nature, available data indicate that variant rearrangements do not confer any specific phenotypic or prognostic impact as compared to CML with a standard Ph chromosome. In most instances, the t(9;22), or a variant thereof, is the sole chromosomal anomaly during the chronic phase (CP) of the disease, whereas additional genetic changes are demonstrable in 60–80% of cases in blast crisis (BC). The secondary chromosomal aberrations are clearly nonrandom, with the most common chromosomal abnormalities being +8 (34% of cases with additional changes), +Ph (30%), i(17q) (20%), +19 (13%), –Y (8% of males), +21 (7%), +17 (5%), and monosomy 7 (5%). We suggest that all these aberrations, occurring in >5% of CML with secondary changes, should be denoted major route abnormalities. Chromosome segments often involved in structural rearrangements include 1q, 3q21, 3q26, 7p, 9p, 11q23, 12p13, 13q11–14, 17p11, 17q10, 21q22, and 22q10. No clear-cut differences as regards type and prevalence of additional aberrations seem to exist between CML with standard t(9;22) and CML with variants, except for slightly lower frequencies of the most common changes in the latter group. The temporal order of the secondary changes varies, but the preferred pathway appears to start with i(17q), followed by +8 and +Ph, and then +19. Molecular genetic abnormalities preceding, or occurring during, BC include overexpression of the BCR/ABL transcript, upregulation of the EVI1 gene, increased telomerase activity, and mutations of the tumor suppressor genes RB1, TP53, and CDKN2A. The cytogenetic evolution patterns vary significantly in relation to treatment given during CP. For example, +8 is more common after busulfan than hydroxyurea therapy, and the secondary changes seen after interferon-alpha treatment or bone marrow transplantation are often unusual, seemingly random, and occasionally transient. Apart from the strong phenotypic impact of addition of acute myeloid leukemia/myelodysplasia-associated translocations and inversions, such as inv(3)(q21q26), t(3;21)(q26;q22), and t(15;17)(q22;q12–21), in CML BC, only a few significant differences between myeloid and lymphoid BC are discerned, with i(17q) and TP53 mutations being more common in myeloid BC and monosomy 7, hypodiploidy, and CDKN2A deletions being more frequent in lymphoid BC. The prognostic significance of the secondary genetic changes is not uniform, although abnormalities involving chromosome 17, e.g., i(17q), have repeatedly been shown to be ominous. However, the clinical impact of additional cytogenetic and molecular genetic aberrations is most likely modified by the treatment modalities used.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
A minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
Structural organization of the bcr gene and its role in the Ph′ translocation
Heisterkamp, N., Stam, K., Groffen, J., de Klein, A., & Grosveld, G. (1985) · Nature · doi:10.1038/315758a0 · Cited by 882
Clonal origin of chronic myelocytic leukemia in man.
Fialkow, P. J., Gartler, S. M., & Yoshida, A. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.4.1468 · Cited by 525
Drexler, H. (1998) · Leukemia · doi:10.1038/sj.leu.2401043 · Cited by 426
Recurrent chromosome aberrations in cancer
Mitelman, F. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00006-5 · Cited by 346
Self-citationMitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M., & Hirai, H. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06288.x · Cited by 325
AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia
Nucifora, G., & Rowley, J. (1995) · Blood · doi:10.1182/blood.v86.1.1.bloodjournal8611 · Cited by 324
Virtaneva, K., Wright, F. A., Tanner, S. M., Yuan, B., Lemon, W. J., Caligiuri, M. A., Bloomfield, C. D., de la Chapelle, A., & Krahe, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1124 · Cited by 311
Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S., & Cline, M. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6783 · Cited by 284
Chronic myelogenous leukemia in blast crisis
Kantarjian, H. M., Keating, M. J., Talpaz, M., Walters, R. S., Smith, T. L., Cork, A., McCredie, K. B., & Freireich, E. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90754-6 · Cited by 277
p53 in chronic myelogenous leukemia in acute phase.
Feinstein, E., Cimino, G., Gale, R. P., Alimena, G., Berthier, R., Kishi, K., Goldman, J., Zaccaria, A., Berrebi, A., & Canaani, E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6293 · Cited by 220
Sill, H., Goldman, J., & Cross, N. (1995) · Blood · doi:10.1182/blood.v85.8.2013.bloodjournal8582013 · Cited by 197
Lichtman, M. A., Spivak, J. L., BOXER, L., et al. (2000) · Elsevier eBooks · doi:10.1016/b978-012448510-5/50134-5 · Cited by 187
A Possible Specific Chromosome Abnormality in Human Chronic Myeloid Leukæmia
Baikie, A. G., COURT-BROWN, W. M., BUCKTON, K. E., Harnden, D. G., Jacobs, P. A., & Tough, I. M. (1960) · Nature · doi:10.1038/1881165a0 · Cited by 181
Clinical Implications of Cytogenetic Variants in Chronic Myelocytic Leukemia (CML)
Whang‐Peng, J., Canellos, G. P., Carbone, P. P., & TJIO, J. H. (1968) · Blood · doi:10.1182/blood.v32.5.755.755 · Cited by 179
The chromosomes in ontogeny and oncogeny.
Hauschka, T. S. (1961) · PubMed · Cited by 174
Caspersson, T., Gahrton, G., Lindsten, J., & Zech, L. (1970) · Experimental Cell Research · doi:10.1016/0014-4827(70)90362-9 · Cited by 172
Johansson, B., Mertens, F., & Mitelman, F. (1996) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199607)16:3<155::aid-gcc1>3.0.co;2-y · Cited by 169
Self-citationClaxton, D., Liu, P., Hsu, H., Marlton, P., Hester, J., Collins, F., Deisseroth, A., Rowley, J., & Siciliano, M. (1994) · Blood · doi:10.1182/blood.v83.7.1750.1750 · Cited by 166
The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.
Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., Allen, S. L., Goldman, J., Snyder, D., Foti, A., & Cline, M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115234 · Cited by 161
Gaiger, A., Henn, T., Horth, E., Geissler, K., Mitterbauer, G., Maier-Dobersberger, T., Greinix, H., Mannhalter, C., Haas, O., & Lechner, K. (1995) · Blood · doi:10.1182/blood.v86.6.2371.bloodjournal8662371 · Cited by 160
Is the chromosomal region 9q34 always involved in variants of the Ph1 translocation?
Hagemeijer, A., Bartram, C. R., Smit, E. M. E., van Agthoven, A. J., & Bootsma, D. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90083-9 · Cited by 158
Chromosomal Evolution in Cell Populations
Hsü, T. C. (1962) · International review of cytology · doi:10.1016/s0074-7696(08)60539-2 · Cited by 155
Kelman, Z., Prokocimer, M., PELLER, S., Kahn, Y., Rechavi, G., Manor, Y. S., Cohen, A., & Rotter, V. (1989) · Blood · doi:10.1182/blood.v74.7.2318.2318 · Cited by 151
Non‐random karyotypic evolution in chronic myeloid leukemia
Mitelman, F., Levan, G., Nilsson, P., & Brandt, L. P. A. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910180105 · Cited by 146
Self-citationChromosomal Abnormalities in Human Neoplasia
Sandberg, A. A., & Hossfeld, D. K. (1970) · Annual Review of Medicine · doi:10.1146/annurev.me.21.020170.002115 · Cited by 146
Wada, C., Shionoya, S., Fujino, Y., Tokuhiro, H., Akahoshi, T., Uchida, T., & Ohtani, H. (1994) · Blood · doi:10.1182/blood.v83.12.3449.3449 · Cited by 137
Sokal, J., Gomez, G., Baccarani, M., Tura, S., Clarkson, B., Cervantes, F., Rozmán, C., Carbonell, F., Anger, B., & Heimpel, H. (1988) · Blood · doi:10.1182/blood.v72.1.294.294 · Cited by 130
Tatematsu, K., Nakayama, J., Danbara, M., Shionoya, S., Sato, H., Omine, M., & Ishikawa, F. (1996) · PubMed · Cited by 121
Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia
Ahuja, H., Jat, P., Foti, A., Bar‐Eli, M., & Cline, M. (1991) · Blood · doi:10.1182/blood.v78.12.3259.3259 · Cited by 119
Nakayama, H., Ishimaru, F., Avitahl, N., Sezaki, N., Fujii, N., Nakase, K., Ninomiya, Y., Harashima, A., Minowada, J., Tsuchiyama, J., et al. (1999) · PubMed · Cited by 118
Höglund, M., Johansson, B., Pedersen-Bjergaard, J., Marynen, P., & Mitelman, F. (1996) · Blood · doi:10.1182/blood.v87.1.324.bloodjournal871324 · Cited by 115
Self-citationZion, M., Ben‐Yehuda, D., Avraham, A., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10722 · Cited by 105
Molecular genetic basis of pancreatic adenocarcinoma
Hilgers, W., & Kern, S. E. (1999) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199909)26:1<1::aid-gcc1>3.0.co;2-x · Cited by 105
Geographic heterogeneity of neoplasia‐associated chromosome aberrations
Johansson, B., Mertens, F., & Mitelman, F. (1991) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870030102 · Cited by 103
Self-citationAssociation of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia
Rubin, C., Larson, R. A., Bitter, M., Carrino, J. J., Beau, M. M. L., Diaz, M., & Rowley, J. (1987) · Blood · doi:10.1182/blood.v70.5.1338.1338 · Cited by 97
The karyotype of blastic crisis
Alimena, G., Cuia, M. R. D., Diverio, D., Gastaldi, R., & Nanni, M. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90131-2 · Cited by 93
Mccarthy, D., Goldman, J. M., Rassool, F., Graham, S. V., & Birnie, G. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92058-0 · Cited by 90
Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression
Ohyashiki, K., Jh, O., Iwama, H., Hayashi, S., Shay, J., & Toyama, K. (1997) · Leukemia · doi:10.1038/sj.leu.2400560 · Cited by 89
Cytogenetic Evidence for Splenic Origin of Blastic Transformation in Chronic Myeloid Leukaemia
Mitelman, F., Brandt, L. P. A., & Nilsson, P. G. (1974) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1974.tb00240.x · Cited by 85
Self-citationChromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia
Prigogina, E. L., Fleischman, E. W., Волкова, М. А., & Frenkel, M. A. (1978) · Human Genetics · doi:10.1007/bf00273096 · Cited by 84
Cogswell, P., Morgan, R., Dunn, M. W., Neubauer, A., Nelson, P., Poland-Johnston, N., Sandberg, A., & Liu, E. (1989) · Blood · doi:10.1182/blood.v74.8.2629.2629 · Cited by 83
Towatari, M., Adachi, K., Kato, H., & Saito, H. (1991) · Blood · doi:10.1182/blood.v78.9.2178.2178 · Cited by 81
Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia
Nelkin, B. D., Przepiorka, D., Burke, P., Thomas, E., & Baylin, S. (1991) · Blood · doi:10.1182/blood.v77.11.2431.2431 · Cited by 81
Translocation of c-abl to “Masked” Ph in chronic myeloid leukemia
Hagemeijer, A., de Klein, A., Gödde-Salz, E., Turc‐Carel, C., Smit, E., van Agthoven, A. J., & Grosveld, G. C. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90059-7 · Cited by 80
Clonal Origin of Chronic Myelocytic Leukemia
Barr, R. D., & Fialkow, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197308092890608 · Cited by 80
p16INK4A and p15INK4B gene deletions in primary leukemias
Haidar, M., Cao, X., Manshouri, T., Chan, L. L., Glassman, A. B., Kantarjian, H., Keating, M. J., Beran, M., & Albitar, M. X. (1995) · Blood · doi:10.1182/blood.v86.1.311.bloodjournal861311 · Cited by 76
Mori, N., Roberta Morosetti, A., Spira, S., Lee, S., Ben‐Yehuda, D., Schiller, G. J., Landolfi, R., Mizoguchi, H., & Koeffler, H. P. (1998) · Blood · doi:10.1182/blood.v92.9.3405 · Cited by 74
Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.
Ogawa, S., Kurokawa, M., Tanaka, T., Tanaka, K., Hangaishi, A., Mitani, K., Kamada, N., Yazaki, Y., & Hirai, H. (1996) · PubMed · Cited by 74
Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.
Majlis, A., Smith, T. L., Talpaz, M., O'Brien, S., Rios, M. B., & Kantarjian, H. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.196 · Cited by 74
Ras oncogene mutations are rare late stage events in chronic myelogenous leukemia
LeMaistre, A., Lee, M., Talpaz, M., Kantarjian, H., Freireich, E., Deisseroth, A., Trujillo, J., & Stass, S. A. (1989) · Blood · doi:10.1182/blood.v73.4.889.889 · Cited by 69
Sonta, S., & Sandberg, A. (1977) · Blood · doi:10.1182/blood.v50.4.691.691 · Cited by 69
Chromosome Banding Studies in Philadelphia Chromosome Positive Myeloid Leukaemia
Lawler, S. D., O’Malley, F. P., & Lobb, D. (1976) · Scandinavian Journal of Haematology · doi:10.1111/j.1600-0609.1976.tb02836.x · Cited by 68
Chronic myeloid leukemia from basics to bedside
Thijsen, S. F. T., Schuurhuis, G. J., Oostveen, J. W. V., & Ossenkoppele, G. J. (1999) · Leukemia · doi:10.1038/sj.leu.2401565 · Cited by 68
Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia
Potter, A. M., Watmore, A. E., Cooke, P., Lilleyman, J. S., & Sokol, R. J. (1981) · British Journal of Cancer · doi:10.1038/bjc.1981.146 · Cited by 68
Collins, S., Howard, M., Df, A., Agura, E. D., & Radich, J. P. (1989) · Blood · doi:10.1182/blood.v73.4.1028.1028 · Cited by 67
A NEW TRANSLOCATION RELATED TO THE PHILADELPHIA CHROMOSOME
Hayata, I., Kakati, S., & Sandberg, A. A. (1973) · The Lancet · doi:10.1016/s0140-6736(73)93346-1 · Cited by 66
Yamamoto, K., Nakamura, Y., Nakamura, Y., Saito, K., & Furusawa, S. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02003.x · Cited by 66
Foti, A., Ahuja, H., Allen, S. L., Koduru, P. R. K., Schuster, M., Schulman, P., Bar‐Eli, M., & Cline, M. (1991) · Blood · doi:10.1182/blood.v77.11.2441.2441 · Cited by 65
The Philadelphia chromosome in human macrophages
Golde, D. W., Burgaleta, C., Rs, S., & Cline, M. (1977) · Blood · doi:10.1182/blood.v49.3.367.367 · Cited by 64
NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia
Ahuja, H. G., Popplewell, L. L., Tcheurekdjian, L., & Slovak, M. L. (2001) · Genes Chromosomes and Cancer · Cited by 63
Serra, A., Gottardi, E. M., Ragione, F. D., Saglio, G. N., & Iolascon, A. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb05358.x · Cited by 62
Swolin, B., Weinfeld, A., Westin, J., Waldenström, J., & Magnusson, B. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90041-x · Cited by 61
Neubauer, A., He, M., Schmidt, C. A., Huhn, D., & Liu, E. T. (1993) · PubMed · Cited by 60
Variant Ph translocations in chronic myeloid leukemia
Heim, S., Billström, R., Kristoffersson, U., Mandahl, N., Strömbeck, B., & Mitelman, F. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90086-x · Cited by 59
Self-citationGahrton, G., Lindsten, J., & Zech, L. (1974) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1974.tb01024.x · Cited by 56
Ishihara, T., & Minamihisamatsu, M. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90314-7 · Cited by 53
Jennings, B. A., & Mills, K. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00097-6 · Cited by 53
Cervantes, F., Rozman, M., Rosell, J., Urbano-Ispizúa, Á., Montserrat, E., & Rozmán, C. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07832.x · Cited by 51
Molecular characteristics of chronic myelogenous leukemia in blast crisis
Blick, M. B., Romero, P., Talpaz, M., Kurzrock, R., Shtalrid, M., Andersson, B. S., Trujillo, J. M., Beran, M., & Gutterman, J. U. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90018-5 · Cited by 44
Anastasi, J., Feng, J., Beau, M. M. L., Larson, R. A., Rowley, J. D., & Vardiman, J. (1995) · PubMed · Cited by 44
Alterations ofP53andRBGenes and the Evolution of the Accelerated Phase of Chronic Myeloid Leukemia
Beck, Z., Kiss, A., Tóth, F., Szabó, J., Bácsi, A., Balogh, E., Borbély, Á., Telek, B., Kovács, E. M., Oláh, É., et al. (2000) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190009059278 · Cited by 43
Chronic myelogenous leukaemia – new therapeutic principles
O'Dwyer, M. E., & Druker, B. J. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00823.x · Cited by 43
Bernstein, R., Pinto, M. R., Wallace, C., Penfold, G. K., & Mendelow, B. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90034-7 · Cited by 41
Collins, S., & Groudine, M. T. (1987) · Blood · doi:10.1182/blood.v69.3.893.893 · Cited by 40
Transposition of 9q34 and 22 (q11?qter) regions has a specific role in chronic myelocytic leukemia
Pasquali, F., Casalone, R., Francesconi, D., Peretti, D., Fraccaro, M., Bernasconi, C., & Lazzarino, M. (1979) · Human Genetics · doi:10.1007/bf00284598 · Cited by 39
A Chromosomal Theory of Carcinogenesis
GROUCHY, J. D., & NAVA, C. D. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-2-381 · Cited by 33
de Greef, G. E., Hagemeijer, A., Morgan, R., Wijsman, J., Hoefsloot, L. H., Sandberg, A. A., & Sacchi, N. (1995) · PubMed · Cited by 33
Cervantes, F., Ballesta, F., Milà, M., & Rozmán, C. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90004-x · Cited by 26
G/G Translocation and chronic myelocytic leukaemia
Bottura, C., & Coutinho, V. (1974) · Annals of Hematology · doi:10.1007/bf01634125 · Cited by 20
Absence of microsatellite instability during the progression of chronic myelocytic leukemia
Mori, N., Takeuchi, S., Tasaka, T., Lee, S. W., Spira, S., Ben‐Yehuda, D., Mizoguchi, H., Schiller, G. J., & Koeffler, H. (1997) · Leukemia · doi:10.1038/sj.leu.2400524 · Cited by 20
Genomic diversity of Philadelphia-positive chronic myelogenous leukemia
Verma, R. S., & Macera, M. J. (1987) · Leukemia Research · doi:10.1016/0145-2126(87)90068-3 · Cited by 19
Ge, X.-Q., Tanaka, K. J., Mansyur, A., Tazawa, H., Iwato, K., Kyo, T., Dohy, H., & Kamada, N. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00394-0 · Cited by 16
Value of cytogenetic studies in prediction of acute phase CML
Watmore, A. E., Potter, A. M., Sokol, R. J., & Wood, J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90195-5 · Cited by 15
Steer, E. J., Goldman, J. M., & Cross, N. C. P. (2001) · Leukemia · doi:10.1038/sj.leu.2402062 · Cited by 10
Unusual Ph translocations in the French prospective study on chronic myeloid leukemia
GROUPEFRANCAISDECYTOGENETIQUE (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90238-9 · Cited by 10
High Frequency of RAS Oncogene Mutation in Chronic Myeloid Leukemia Patients with Myeloblastoma
Tanaka, K. J., Takauchi, K., Takechi, M., Kyo, T., Dohy, H., & Kamada, N. (1994) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199409056296 · Cited by 9
Application of Log-Linear Model in Inference on Karyotypic Evolution in Chronic Myelocytic Leukemia
Hashimoto, T., Ohtaki, M., Kamada, N., Yamamoto, H., & Munaka, M. (1990) · Environmental Health Perspectives · doi:10.1289/ehp.9087135 · Cited by 6
Cited by
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
Self-citationA Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Metadata
- Authors
- Johansson, B., Fioretos, T., & Mitelman, F.
- Venue
- Acta Haematologica
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 107
- Issue
- 2
- Pages
- 76-94
- ISSN
- 0001-5792 (ISSN-L)
- 1421-9662
- OpenAlex
- W2038538605
- Cited by
- 454
- References
- 92
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.